MétaCan
Menu
Back to cohort
Record W4410755415 · doi:10.1111/bju.16793

Impact of concomitant carcinoma in situ distribution on non‐muscle‐invasive bladder cancer progression risk

2025· article· en· W4410755415 on OpenAlexaff
Jethro C.C. Kwong, Zizo Al‐Daqqaq, Yashan Chelliahpillai, Soomin Lee, Kellie Kim, Maximiliano Ringa, Amna Ali, Marian S. Wettstein, Amy Chan, Katherine Lajkosz, Theodorus van der Kwast, Nathan Perlis, Jason Y. Lee, Robert J. Hamilton, Neil Fleshner, Antonio Finelli, Munir Jamal, Frank Papanikolaou, Thomas Short, Andrew Feifer, Girish S. Kulkarni, Alexandre R. Zlotta

Bibliographic record

VenueBritish Journal of Urology · 2025
Typearticle
Languageen
FieldMedicine
TopicBladder and Urothelial Cancer Treatments
Canadian institutionsSinai Health SystemMount Sinai HospitalTrillium Health CentreUniversity of TorontoUniversity Health Network
Fundersnot available
KeywordsConcomitantCarcinoma in situMedicineBladder cancerInterquartile rangeHazard ratioInternal medicineRetrospective cohort studyOncologyUrologyCancerConfidence intervalPathology

Abstract

fetched live from OpenAlex

OBJECTIVE: To assess whether the distribution of concomitant carcinoma in situ (CIS; unifocal or multifocal) with papillary non-muscle-invasive bladder cancer (NMIBC) impacts the risk of progression, as concomitant CIS is an established risk factor for progression in papillary NMIBC and commonly used calculators do not make this distinction. PATIENTS AND METHODS: In this multi-institutional retrospective cohort study from both academic and community hospitals, clinicopathological data were collected from patients with pTa/pT1 NMIBC treated from 2005 to 2022. Unifocal concomitant CIS was defined as CIS present in only one specimen (i.e., papillary disease with CIS at the tumour base or isolated CIS in one specimen). Multifocal concomitant CIS was characterised by CIS in multiple specimens. Progression was defined as the development of muscle-invasive or metastatic disease. Fine-Gray regression was performed to identify progression-associated factors, using all-cause mortality as a competing risk. RESULTS: Among 2923 patients, 383 (13%) progressed over a median (interquartile range) follow-up of 5.1 (3.0-8.5) years. Concomitant CIS was found in 327 patients (11%), with 233 and 94 harbouring unifocal and multifocal CIS, respectively. Recurrent tumours, T1 stage, high-grade disease, multifocal CIS, and multiple tumours were independently associated with increased progression risk (all P < 0.05). Among patients with concomitant CIS, multifocal CIS remained a significant prognosticator (sub-distribution hazard ratio 1.90, 95% confidence interval 1.18-3.05; P = 0.008) adjusting for age, sex, tumour history, stage, grade, number of tumours, tumour diameter, and Bacillus Calmette-Guérin treatment. CONCLUSIONS: Papillary NMIBC progression risk varies with concomitant CIS distribution. Only multifocal concomitant CIS is a risk factor for progression in patients with T1 NMIBC. If validated in further studies, risk calculators should consider including this CIS distinction. Submitting separate specimens at the time of transurethral resection, as recommended by guidelines, should be encouraged.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.314
Teacher spread0.303 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueBritish Journal of UrologySame topicBladder and Urothelial Cancer TreatmentsFrench-language works237,207